Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Conditions
Keywords
GIB, UGIB
Brief summary
Early endoscopy is an integral part of the management plan for patients presenting with clinical signs of severe or ongoing UGIB. An accurate endoscopic diagnosis and successful endoscopic hemostasis is highly dependent on adequate visualization of the entire gastric mucosa. Metoclopramide has previously been investigated as a prokinetic agent to aid gastric emptying prior to endoscopy, but its widespread adoption is limited by a lack of high quality clinical evidence as well as concerns regarding side effects. Erythromycin is currently the only prokinetic agent recommended by the American and the European guidelines for use in selected patients in order to reduce the need for second endoscopy. Its clinical application, however, is limited by risk of arrhythmia, significant drug interactions, and frequent drug shortages. Azithromycin is structurally related to erythromycin, but is devoid of most adverse side effects associated with erythromycin use. Early evidence suggests that azithromycin may be an effective alternative to erythromycin in the treatment of gastroparesis. The current study, an interventional, randomized, triple-blinded, placebo-controlled clinical trial, is primarily aimed to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB. It is also aimed to further evaluate the role of metoclopramide as a prokinetic agent in this setting. Outcome measures to be collected in this study include the need for secondary endoscopy, overall mortality, transfusion requirement, length of stay, requirement for surgery, and incidence of adverse side effects. Results from this study would help identify a safe, effective, and readily available prokinetic agent to be used prior to endoscopy.
Interventions
Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
DRUGMetoclopramide Injectable Solution
Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
DRUGSodium chloride 0.9%
Normal saline is used as a placebo control.
Sponsors
Waihong Chung
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Initial management of UGIB would be performed by the primary team without interference from the investigator. If a gastroenterology consult were placed by the primary team, the endoscopist on-call would evaluate the patient per routine care. If an early endoscopy is deemed appropriate and necessary based on the patient's clinical status, the participant is registered to a central electronic database, which would assign participants to the intervention arm or the placebo arm using a permuted block randomization process. The appropriate medication or placebo is prepared and distributed by the central inpatient pharmacy. The investigator, the endoscopist, the study participant, and the primary team are all blinded to the assignment.
Intervention model description
The study is comprised of two intervention arms, namely the azithromycin arm and the metoclopramide arm, as well as one placebo arm. The two interventions would be studied sequentially in order to simplify the logistical challenges of the blinding and placebo-control processes. The current study is comprised to two parts. During Part 1 of the study, participants are randomized to either azithromycin 500mg intravenous infusion or equivalent volume of 0.9% sodium chloride infusion in a 2-to-1 ratio. During Part 2 of the study, participants are randomized to either metoclopramide 10mg intravenous injection or equivalent volume of 0.9% sodium chloride injection in a 2-to-1 ratio. The 0.9% sodium chloride arm from the two parts of the study are pooled together to form the placebo arm during final analysis.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Adult patients ≥ 18 years of age at the time of presentation; * 2\. Admitted to Rhode Island Hospital (RIH) emergency room or inpatient services; * 3\. Presented with hematemesis, coffee ground emesis, or melena; * 4\. Upper endoscopy is planned within 24 hours of presentation or onset of bleeding.
Exclusion criteria
* 1\. Known anaphylactic allergic reaction to erythromycin, azithromycin, and/or metoclopramide; * 2\. Concurrent use of certain medications associated with tardive dyskinesia (TD): * a. Fluphenazine, * b. Haloperidol, * c. Loxapine, * d. Paliperidone, * e. Perphenazine, * f. Pimozide, * g. Risperidone, * h. Thiothixene, * i. Trifluoperazine; * 3\. Concurrent use of certain medications associated with torsade de pointes: * a. Amiodarone, * b. Chlorpromazine, * c. Disopyramide, * d. Dofetilide, * e. Methadone, * f. Procainamide, * g. Quinidine, * h. Sotalol; * 4\. Known history of TD, ventricular arrhythmias , or long QT syndrome; * 5\. Already received erythromycin and/or azithromycin within the past 10 days, or metoclopramide within the past 4 days for other indications; * 6\. Recipient of hematopoietic stem cell transplant; * 7\. History of Neisseria gonorrhoeae infection; * 8\. Pregnancy; * 9\. Prior gastrectomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Neurological Side Effects related to Intervention | 48 hours | The primary neurological outcome measure is the incidence of any reversible or irreversible extrapyramidal symptom, such as acute dystonic reactions, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, within 48 hours of metoclopramide administration. |
| Rate of Reduction in the Need for Second Endoscopy | 48 hours | The primary outcome measure of effectiveness is a reduction in the need for second endoscopy within 48 hours of the first endoscopy. This primary outcome measure is chosen because it represents the basis of current American and European guideline recommendations regarding erythromycin. |
| Adverse Cardiac Side Effects related to Intervention | 5 days | The primary cardiac outcome measure is the incidence of unstable arrhythmia, occurring within 5 days of azithromycin administration, requiring cardioversion or resulting in cardiac arrest. |
| Adverse Infectious Disease Side Effects related to Intervention | 30 days | The primary infectious disease outcome measure is the incidence of C. difficile infection, occurring within 30 days of azithromycin administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Endoscopic Visualization | 48 hours | Endoscopic visibility is graded using the standard 4-point objective scoring system as described in most endoscopy literature. The corpus, fundus, and duodenal bulb are scored separately based on an independent review of the images captured by the endoscopist. If a second endoscopy is performed within 48 hours of the initial endoscopy, the presence of clinically significant lesions not identified during the first endoscopy is also measured. |
| All-Cause Mortality | 30 days. | All-Cause Mortality within 30 days. |
| Number of Unit of Transfusion | 30 days | Number of units of packed red blood cells transfused before hemostasis has been achieved or death. |
| Length of Hospital Stay | 30 days | Length of hospital stay since admission for current episode of GIB. |
Countries
United States
Contacts
Primary ContactWaihong Chung, MD PhD
Outcome results
None listed